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AbsTrACT
Objective Early mortality rates for paediatric cardiac 
surgery have fallen due to advancements in care. 
Alternative indicators of care quality are needed. 
Postoperative morbidities are of particular interest. 
However, while health impacts have been reported, 
associated costs are unknown. Our objective was to 
calculate the costs of postoperative morbidities following 
paediatric cardiac surgery.
Design Two methods of data collection were integrated 
into the main study: (1) case- matched cohort study of 
children with and without predetermined morbidities;  
(2) incidence rates of morbidity, measured prospectively.
setting Five specialist paediatric cardiac surgery 
centres, accounting for half of UK patients.
Patients Cohort study included 666 children (340 with 
morbidities). Incidence rates were measured in 3090 
consecutive procedures.
Methods Risk- adjusted regression modelling to 
determine marginal effects of morbidities on per- 
patient costs. Calculation of costs for hospital providers 
according to incidence rates. Extrapolation using 
mandatory audit data to report annual financial burden 
for the health service.
Outcome measures Impact of postoperative 
morbidities on per- patient costs, hospital costs and UK 
health service costs.
results Seven of the 10 morbidity categories resulted 
in significant costs, with mean (95% CI) additional costs 
ranging from £7483 (£3–£17 289) to £66 784  
(£40 609–£103 539) per patient. On average all 
morbidities combined increased hospital costs by 22.3%. 
Total burden to the UK health service exceeded £21 
million each year.
Conclusion Postoperative morbidities are associated 
with a significant financial burden. Our findings could aid 
clinical teams and hospital providers to account for costs 
and contextualise quality improvement initiatives.
InTrODuCTIOn
Each year more than 5000 paediatric cardiac 
surgery procedures are performed in the UK.1 
Advancements in preoperative, perioperative and 
postoperative care have transformed outcomes, 
greatly reducing mortality in the immediate postop-
erative period.2 Patients with complex heart defects 
and pre- existing conditions now routinely survive 
surgery.3 Alternative measures of care quality are 
needed; postoperative morbidities are considered 
the next important challenge for clinical teams.
Early postoperative morbidities are defined as 
adverse effects on health which are linked to a 
surgical procedure. The Multi- Societal Database 
Committee for Pediatric and Congenital Heart 
Disease published a series of articles addressing 
the impact of postoperative morbidities4–9 and the 
Society of Thoracic Surgery explored complication 
rates within this database.10 This work established 
that morbidities prolong hospital stay and increase 
the risk of further complications and death.11 
Where costs of postoperative morbidities have 
been reported, they are predominately limited to 
measuring variations in hospital costs in relation to 
outcomes.12–14 In the UK, work by our group15 and 
a major review of the specialty16 calls for outcomes 
including morbidity, to be monitored in a mean-
ingful way.
Our analysis uses prospective, patient- level 
cohort data and incidence rates to calculate the 
impact of morbidities on per- patient costs, hospital 
costs and annual financial burden for the UK health 
system.
MeThODs
study overview
This study was one element of a 5- year research 
project to select and define important early morbid-
ities linked to paediatric cardiac surgery and 
measure their incidence and impact for UK chil-
dren.17 The objective of the economic analysis was 
to calculate the costs of postoperative morbidities 
following paediatric cardiac surgery.
Regression modelling of patient- level data from 
a prospective, case- matched cohort study of 666 
children was used to measure hospital resource 
use in patients with and without morbidities. The 
What is already known on this topic?
 ► There is no evidence which accurately describes 
the cost of early morbidities following 
paediatric cardiac surgery.
What this study adds?
 ► This is the first prospective economic analysis 
to report the significant costs associated with 
morbidities for this population at the patient, 
provider and national levels.
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incidence of morbidities for 3090 consecutive surgical proce-
dures was measured contemporaneously by study centres 
(incidence data set), facilitating further analysis of costs at the 
provider level and an extrapolation using national mandatory 
audit data to estimate the annual financial burden on the UK 
health service.
setting
Patients were recruited from October 2015 to June 2017 in 
five UK centres (Birmingham Children’s Hospital, Bristol Chil-
dren’s Hospital, Evelina London Children’s Hospital, Great 
Ormond Street Hospital for Children NHS Foundation Trust, 
The Royal Hospital for Sick Children Glasgow). Patients and the 
public were involved in the wider study but not directly in the 
economic analysis.
Patients
The study recruited children from birth to 17 years of age, under-
going open and closed cardiac surgery procedures subject to 
audit by the National Congenital Heart Disease Audit (NCHDA) 
(online supplementary appendix 1).
Families with children who met the inclusion criteria were 
approached to take part in the cohort study unless they were 
not UK residents, or no family member spoke sufficient English 
to participate.
The following patients were excluded:
 ► Premature babies undergoing persistent ductus arteriosus 
ligation.
 ► Those undergoing cardiothoracic transplant and tracheal 
surgeries.
 ► Those undergoing isolated interventional cardiology 
procedures.
Each centre attempted to match children with and without 
morbidities by age, ventricle status (defects of one or both 
cardiac ventricles) and surgical procedure.17
Classification of morbidities
Predefined morbidities were extracorporeal life support 
(ECLS), acute neurological event, unplanned reintervention, 
feeding problems, major adverse event, prolonged pleural 
effusion, postsurgical infection morbidity, renal support and 
necrotising enterocolitis. Definitions have been published 
previously18 and are summarised in online supplementary 
appendix 2.
Patients were categorised as follows:
 ► Children without postoperative morbidity.
 ► Children who experienced a single morbidity (not ECLS).
 ► Children who experienced more than one morbidity not 
including ECLS .
 ► Children who needed postoperative ECLS whether on its 
own or in combination with other morbidities.
Data collection
The observation period commenced on the day of the qualifying 
surgical procedure (day 1) and concluded 6 months later (day 
183). Hospital costs were a summation of: operating theatre 
costs for the initial surgery and any additional procedures; high 
dependency/intensive care unit (ICU) costs; ward costs and all 
outpatient visit costs during the observation period. For chil-
dren who died within the observation period (n=39), data were 
collected until the date of death.
Resource use
Operating theatre time (minutes) and number of ward days were 
extracted from hospital information systems. ICU data were 
extracted from the Paediatric Intensive Care Audit Network 
database. Number of outpatient visits was reported by families at 
follow- up visits (6, 12 and 26 weeks). Research staff monitored 
data for accuracy.
Unit costs
Unit costs were obtained from published sources19–21 and 
inflated (2016/2017 UK£) where necessary. Healthcare resource 
groups were assigned for each day of ICU stay: intensive care 
extracorporeal membrane oxygenation (ECMO)/ECLS (cost 
per day £5440); intensive care advanced enhanced (£3748); 
intensive care advanced (£2538); intensive care basic enhanced 
(£2151); intensive care basic (£1899); high dependency 
advanced (£1448); high dependency (£1173); and enhanced 
care (£870).19 The daily ward cost of the study centre closest to 
the mean value for all centres was used; £904 for children <2 
years and £680 for children ≥2 years. For operating theatres, 
the cost per minute closest to the mean across centres (£13.39) 
was used. Each outpatient visit was assigned published national 
average costs for paediatric outpatient visits (£199).19
Data analysis
Handling missing data
Measures of inpatient resource had 3%–14% of missing data. 
Outpatient attendance was reliant on self- reporting, 19% of data 
were missing. Multiple imputation to account for missing data 
was undertaken using explanatory variables without missing 
values.22 Twenty imputed data sets were generated using an iter-
ative Markov chain Monte Carlo procedure based on multivar-
iate normal regression.
Case mix adjustment
Confounding variables from the analysis of clinical outcomes 
which were predefined and validated23 were tested using a 
forward selection and backward elimination technique on 
imputed data. Variables with a significant (p value <0.05) associ-
ation with costs were: age, weight by age, congenital morbidity, 
pre- existing severe illness, Down’s syndrome, cardiac diagnosis, 
procedure type, death within 6 months and study centre.
Regression analysis
We used a generalised linear model with gamma family and 
log link, recommended for skewed cost data.24 To account for 
multiple imputation, coefficients and SEs were computed using 
combination rules.22 ‘No morbidities’ was the reference category. 
Coefficients with p values <0.05 were considered significantly 
different from zero. All analyses were performed in Stata v14.25
Per- patient costs are expressed as marginal effects illustrating 
the mean difference in 6- month hospital costs between the 
morbidity category and omitted category (no morbidity), condi-
tional on the covariates. To compute marginal effects we: (1) 
exponentiated the coefficient for each morbidity; (2) multiplied 
this by the mean of the omitted category; and (3) subtracted the 
mean of the omitted category from this product.26
Annual financial burden to the UK health service
The financial burden to the health service is the additional cost 
resulting from treating morbidities in the UK population each 
year. We extrapolated our results to the UK population using the 
following methods:
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I. We calculated the annual incidence rate at each study cen-
tre (A–E) for every morbidity category including the no 
morbidity category (1-11)(eg, [incidence of morbidity cate-
gory at site A/months of observation site A]×12=A1, A2…
A11).
II. We summed the rate of each individual category across all 
study centres (eg, A1+B1+C1+D1+E1= S1); the total of 
which gives the annual number of procedures across all 
study sites (S1+S2…+S11=STOT).
III. We identified the rates of equivalent procedures nationally 
as reported in UK mandatory audits over the same period 
(2014–2017)3 for all National Health Service (NHS) cen-
tres in England, Wales and Scotland. In Ireland, all patients 
are treated at a single centre. To account for Northern Irish 
patients, 28% of cases from this centre were included.27 
The resulting total number of procedures for the UK was 
averaged over the 3 years (PTOT).
IV. We divided the UK population procedure rate by the study 
procedure rate (PTOT/STOT) to calculate an extrapolation 
factor to convert study- specific results to national esti-
mates.
V. We multiplied this extrapolation factor by the incidence 
of each category to estimate the numbers for the UK pop-
ulation and multiplied this by the cost of each category to 
calculate the national annual burden of each morbidity to 
the UK health service.
Costs of morbidities for UK hospital providers
In order to contextualise results for hospital providers we applied 
the per- patient costs to each of the 10 morbidities and the no 
morbidity category to the annual incidence reported by the 12 
UK centres3 and calculated the variation in costs according to 
activity.
resulTs
study population
Six hundred and sixty- six children were recruited to the cohort 
study, the proportion in each category was: no morbidity n=326 
(48.9%), prolonged pleural effusion n=50 (7.5%), feeding 
problems n=45 (6.7%), acute neurological event n=6 (0.9%), 
necrotising enterocolitis n=11 (1.6%), postsurgical infection 
morbidity n=11 (1.6%), unanticipated reintervention n=24 
(3.6%), renal support n=22 (3.3%), major adverse event n=26 
(3.9%), multiple morbidities n=118 (17.7%) and ECLS n=27 
(4.0%). Characteristics of patients with and without morbidities 
are shown in table 1 and by morbidity category in online supple-
mentary appendix 3.
Complete data for 6- month hospital costs (operating theatre 
costs, high dependency/ICU costs, ward costs and outpatient 
visits over the 6- month postoperative period) were available for 
538 (81%).
regression analysis
For children without morbidities, the mean- adjusted 6- month 
predicted cost per patient was £24 143. Regression modelling iden-
tified significant marginal effects (increase from £24 143) in seven 
morbidity categories with mean (95% CI) values of: prolonged 
pleural effusion £7483 (£3–£17 289); renal support £11 241 (£936–
£25 781); necrotising enterocolitis £16 592 (£599–£42 924); 
feeding problems £17 927 (£8057–£30 824); unplanned reinterven-
tion £22 903 (£9598–£41 456); multimorbidities £37 697 (£25 971 
–£52 167); and ECLS £66 784 (£40 609–£103 539) (table 2).
Annual financial burden to the uK health service
The total calculated cost of 6- month postoperative hospital 
services for the UK population was £115 864 753 (£103 
162 820–£128 566 686). If no child incurred early postopera-
tive morbidity this cost would be £94 785 418 (£81 931 327– 
£107 639 509), resulting in an annual financial burden to the 
NHS from early postoperative morbidities of £21 079 335 
(£19 331 430–£22 827 240) (table 3).
Costs of morbidities for hospital service providers
In the UK, there are 12 hospitals performing paediatric cardiac 
surgery with annual procedure rates ranging from 226 to 628,3 
the average rate per centre is 367 procedures, per year. Applying 
per- patient costs, we calculated the cost of 6- month postopera-
tive care for the average hospital to be £9 655 396, of which £1 
756 611 was additional cost from morbidities, representing a 
22.3% increase in costs (table 4). For the centre performing the 
most procedures in the NCHDA, calculated total cost would be 
£18 533 638 with £3 371 834 due to morbidities; for the centre 
performing the fewest procedures, total cost is £6 669 748 with 
a morbidity burden of £1 213 430.
DIsCussIOn
Principal findings
Seven early postoperative morbidities following paediatric 
cardiac surgery were associated with significant increases in per- 
patient 6- month hospital costs compared with the same costs 
for children without morbidity. The magnitude of additional 
resource use for patients who experience morbidities represents 
a substantial cost burden for hospital providers, with an average 
increase in costs for UK centres of 22.3%. When extrapolated to 
the national patient population, the estimated additional finan-
cial burden of early postoperative morbidities for the UK health 
service exceeds £21 million each year.
Given these considerable costs, our data support the argument 
that addressing morbidities should be the next major focus for 
improving outcomes for patients as in addition to clinical gains, 
care quality improvements that reduce morbidities could also be 
highly cost- effective.
strengths and limitations of this research
To our knowledge, this is the first study to report the financial 
impact of clinically important morbidities for this patient popu-
lation. Our analysis uses rich patient- level measures of resource 
use collected specifically for the purpose of measuring costs. 
Measures of hospital resource use had high level of completeness 
and the sample population is representative of the UK patient 
population in terms of conditions, procedures, risk factors and 
outcomes.18
The method of cohort assignment which allocated comparable 
patients to the case and control cohorts is likely to have reduced 
intersite variability, which is a limitation often seen in obser-
vational cohort studies. For children without morbidities, the 
survival rate at 6 months was 99.3%, and the median length of 
stay was 8 days, suggesting that the morbidities selected captured 
the majority of complication- related adverse outcomes for the 
population.23 Monitoring of the incidence of each morbidity 
category in 3090 consecutive procedures across half of all UK 
centres over several years facilitated a credible calculation of 
annual financial burden for the NHS.
The main limitation of our work is that we were only able to 
illustrate costs for the 6- month period following surgery. The 
consequences of this fixed observation period are, first, that for 
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Table 1 Characteristics of cohort study patients with and without morbidities
Variable Category no morbidity n=326 (%) Any morbidity n=340 (%) Total (%)
Sex Female 137 (42) 155 (47) 292 (44)
Male 189 (58) 185 (53) 374 (56)
Income category
(per year)
Up to £10 000 31 (9) 24 (7) 55 (8)
£10 000–£20 000 67 (21) 87 (25) 154 (23)
£20 001–£50 000 118 (36) 113 (34) 231 (35)
More than £50 000 73 (22) 57 (16) 130 (20)
Unknown 37 (12) 59 (18) 96 (14)
Survived beyond 6 months Yes 322 (99) 305 (90) 627 (94)
No 4 35 39 (6)
Hospital centre A 79 (24) 106 (31) 185 (28)
B 69 (21) 66 (19) 135 (20)
C 78 (24) 78 (23) 156 (23)
D 68 (21) 65 (19) 133 (20)
E 32 (10) 25 (4) 57 (9)
Ethnicity White 226 (69) 219 (64) 445 (67)
Non- white 92 (28) 99 (31) 191 (29)
Missing 8 (2) 22 (6) 30 (5)
Weight for age Normal 212 (65) 219 (64) 431 (65)
Low 90 (28) 103 (30) 193 (29)
Missing 24 (7) 18 (5) 42 (6)
Premature* No 300 (92) 306 (90) 606 (91)
Yes 26 34 60 (9)
Congenital comorbidity* No 281 (86) 264 (78) 545 (82)
Yes 45 76 121 (18)
Pre- existing severity of illness indicators* No 277 (85) 265 (78) 542 (81)
Yes 49 75 124 (19)
Preacquired comorbidity* No 279 (85) 290 (85) 569 (85)
Yes 47 50 97 (15)
Down’s syndrome* No 299 (92) 311 (91) 610 (92)
Yes 27 29 56 (8)
Pre- existing additional cardiac risk factor† No 301 (92) 309 (91) 610 (92)
Yes 25 31 56 (8)
Diagnosis category† A (most complex) 40 (12) 48 (14) 88 (14)
B 34 (10) 56 (16) 90 (14)
C 62 (19) 62 (18) 124 (19)
D 89 (27) 107 (31) 196 (29)
E (least complex) 101 (31) 67 (20) 168 (25)
Procedure category‡ A: Palliative/staged 65 (19) 90 (25) 155 (23)
B: Reparative/corrective 190 (58) 169 (50) 359 (54)
C: Ambiguous 71 (22) 81 (24) 152 (23)
Age category Neonate 114 (35) 146 (43) 260 (39)
Infant 130 (40) 120 (35) 250 (38)
Child 82 (25) 74 (22) 156 (23)
*Comorbidities are: preacquired comorbidity; congenital comorbidity excluding Down’s syndrome; Down’s syndrome, additional cardiac risk factors (eg, cardiomyopathy); 
prematurity; severity of illness indicator.
†Cardiac diagnosis category based on the Partial Risk Adjustment in Surgery (PRAiS2) ranking order and further aggregated by an expert panel, group A the most complex and 
group E the least (online supplementary appendix 4).
‡Specific procedure category based on National Congenital Heart Disease Audit (NCHDA) algorithm, reparative or corrective operation; palliative or staging operation; ungrouped 
operation (could not be determined).18
children with the most complex recoveries clinical and cost impacts 
can extend well beyond this time point, and, second, the variation 
in length of stay within the 6- month period directly impacted the 
admissible data collection period for other types of resource use. 
For our sample population, 95% of children without morbidity 
had been discharged from the hospital before 6 weeks, therefore, 
costs of readmissions and outpatient appointments were measured 
for 18 weeks, whereas 30% of children with multiple morbidities 
and 48% of those who had ECLS remained in hospital beyond 
6 weeks and so those same costs were measured over a shorter 
period. To account for this, we have been careful to stipulate that 
our results are representative of the actual costs incurred in the 
6 months following surgery. Nevertheless, since the patients with 
morbidities and a greater length of stay would also have been very 
likely to require more intense follow- up in the out- of- hospital 
phase, extending beyond our 6- month window, their true overall 
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Table 2 Marginal effects of morbidity on 6- month hospital costs 
(imputed data set)
Morbidity category Coefficient P value Marginal effect (95% CI)
Extracorporeal life support 1.326 <0.001 £66 784 (£40 609 to £103 539)
Multiple morbidity (except 
ECLS)
0.941 <0.001 £37 697 (£25 971 to £52 167)
Unplanned reoperation 0.667 <0.001 £22 903 (£9598 to £41 456)
Feeding problems 0.555 <0.001 £17 927 (£8057 to £30 824)
Necrotising enterocolitis 0.523 0.04 £16 592 (£599 to £42 924)
Acute neurological event 0.458 0.21 £14 042 (−£5424 to £53 753)
Renal support 0.382 0.03 £11 241 (£936 to £25 781)
Postsurgical infection 
morbidity
0.347 0.17 £10 025 (−£3266 to £31 779)
Prolonged pleural effusion 0.270 0.05 £7483 (£3 to £17 289)
Major adverse event 0.189 0.32 £5030 (−£4119 to £18 359)
Observations from imputed data, n=666
In every case the regression model was a generalised linear model with gamma family and log link. 
The marginal effects are the change in costs versus the omitted category (no morbidities). Data include 
values imputed using multiple imputation. Costs are in 2016/2017 UK£. Controls were also included 
in every model for: age; weight by age; whether or not the patient had a pre- existing congenital 
morbidity, pre- existing severe illness or Down’s syndrome; underlying diagnosis prompting cardiac 
surgery; type of cardiac procedure performed; whether or not the patient died within 6 months; and 
study centre.
ECLS, extracorporeal life support.
Table 3 Annual financial burden to the UK health service
Morbidity type
Marginal effect on costs 
of morbidity (increase 
from £24 143)
Total per- patient 
cost (cost of no 
morbidity+marginal 
effect)
Annual morbidity 
incidence—study 
centres*
Annual morbidity 
incidence—
extrapolated to uK 
population
Annual cost to health 
service of morbidity
Annual national 
total cost
A B (A×J) C D (C×J) E (A×D) F (B×D)
No morbidity – £24 143 1415.1 3066 – £74 022 438
Acute neurological event £0 £24 143 8.3 18 £0 £434 574
Unplanned reoperation £22 903 £47 046 34.7 75 £1 717 725 £3 528 450
Feeding problems £17 927 £42 070 57.2 124 £2 222 948 £5 216 680
Renal support £11 241 £35 384 23.3 50 £562 050 £1 769 200
Major adverse event £0 £24 143 20.4 44 £0 £1 062 292
Extracorporeal life support £66 784 £90 927 37.5 81 £5 409 504 £7 365 087
Necrotising enterocolitis £16 592 £40 735 19.1 41 £680 272 £1 670 135
Postsurgical infection morbidity £0 £24 143 16.0 35 £0 £845 005
Prolonged pleural effusion £7483 £31 626 65.4 142 £1 062 586 £4 490 892
Multiple morbidity £37 697 £61 840 115.4 250 £9 424 250 £15 460 000
Total 1812.4 3927 £21 079 335 £115 864 753
Total incidence 
nChDA reports 
2014–2017†
Annual incidence 
nChDA reports
Annualtotal morbidity 
incidence—study centres extrapolation factor
Annual total morbidity 
cost for uK patient 
population
Annual national total 
cost
Annual national cost 
with no morbidities
% increase in 
cost
G H (G/3) I J (H/I) K L M (K- L) N ([K/M]×100)
11 782 3927 1812.4 2.167 £21 079 335 £115 864 753 £94 785 418 22.3%
*Calculated from observed incidence rates of 3090 consecutive surgical procedures across all study centres.
†Calculated from reported rates of equivalent procedures in mandatory audit report from NCHDA rounded in this table to one decimal place.
NCHDA, National Congenital Heart Disease Audit.
Table 4 Costs of morbidities to hospital providers
Morbidity type
Annual incidence of 
morbidity averaged 
across 12 nChDA 
centres
Average annual 
marginal cost per 
provider
Average annual 
total cost per 
provider
Table 3,
column D/12
Table 3,
column e/12
Table 3, column 
F/12
No morbidity 255.5 – £6 168 537
Acute neurological event 1.5 £0 £36 215
Unplanned reoperation 6.3 £143 144 £294 038
Feeding problems 10.3 £185 246 £434 723
Renal support 4.2 £46 838 £147 433
Major adverse event 3.7 £0 £88 524
Extracorporeal life support 6.8 £450 792 £613 757
Necrotising enterocolitis 3.4 £56 689 £139 178
Postsurgical infection 
morbidity
2.9 £0 £70 417
Prolonged pleural effusion 11.8 £88 549 £374 241
Multiple morbidity 20.8 £785 354 £1 288 333
Total 327.2 £1 756 611 £9 655 396
NCHDA, National Congenital Heart Disease Audit.
costs would have been even higher than presented here. Further 
research needs to be undertaken to understand the possible cost 
impact of those morbidities which did not significantly increase 
costs as the numbers in these groups were small and it is likely that 
the sample was underpowered.
Non- hospital costs and costs borne by families were recorded 
in this study, however, the variation in follow- up and the signifi-
cant level of missing data meant we were unable to report them. 
Despite the challenges of collecting data these costs warrant 
further research and accurate reporting.
Implications for clinical practice and policy
Benchmarking and public reporting of outcomes are methods 
of comparative assessment used worldwide to drive quality 
improvements.28 29 The NCHDA has reported centre- specific, 
risk- adjusted mortality rates following paediatric cardiac surgery 
since 2005, however a consistent 30- day postoperative mortality 
rate of 2% has prompted clinical teams to look for alternate 
care quality indicators. A rapid literature review in 2017 by the 
Canadian Institute of Health Economics included two studies 
reporting statistically significant reductions in morbidities as 
a result of external benchmarking.30 In terms of our results, a 
crude overall reduction of 5% in yearly incidence of morbidities 
with significant impacts on 6- month hospital costs equates to 
an annual cost saving for the NHS of £1 053 966. With manda-
tory auditing well established in the UK it is conceivable that 
expanding public reporting and benchmarking to include clin-
ically important morbidities could be a cost- effective quality 
improvement initiative.
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unanswered questions and future research
Paediatric cardiac surgery is a highly invasive, traumatic life 
event for children and their families and there is a need to 
advance the reporting of costs beyond morbidity and relate 
them to patients’ postoperative functional status and quality 
of life.
Finally, the methodology we have used, including the use of 
costing and outcome data from a number of sources populated 
as a result of existing reporting, costing and benchmarking 
initiatives, which are not in principle specific to paediatric 
cardiac surgery, provides a template that could be adapted 
more broadly within the NHS to elicit similar insights into 
other areas where the cost of hospitalisation is analogous to 
outcomes of interest.
COnClusIOn
Costs associated with postoperative morbidity following paedi-
atric cardiac surgery are substantial. Our research identifies the 
financial impact of early postoperative morbidities on hospital 
providers of paediatric surgery and the UK NHS. As mortality 
rates improve and increasingly complex patients survive their 
surgery, the cost of postoperative care is likely to rise. Data from 
our analysis could aid clinical teams and hospital providers to 
account for these costs and contextualise potential care quality 
improvement initiatives.
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